Compare Novo Nordisk A/S (NVO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Prospect Capital Corporation — how do they compare? Novo Nordisk A/S trades at $46.12 (market cap $207.85B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Novo Nordisk A/S is far larger — about 182.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| NVO | PSEC | |
|---|---|---|
Market Cap | $207.85B | $1.14B |
Sector | Health | Financials |
52-Week High | $63.98 | $3.05 |
52-Week Low | $35.29 | $2.11 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
PSEC trades at $2.29, down 1.72% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock carries a low P/B of 0.39 and has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $469.92 million in 2025. Recent news includes a dividend increase announcement and the sale of portfolio company Valley Electric for $328 million.
The outlook is cautious; while the deep discount to book value and consistent dividend payments offer income appeal, significant negative revenue and net income margins, alongside a divided analyst consensus, highlight substantial business and market risks. The primary opportunity lies in a potential valuation recovery if operational performance improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
